TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Health & Fitness

    Neurology® Podcast

    The Neurology Podcast provides practical information for neurologists and clinicians to practice the best possible medicine for patients. Examining methods and findings in peer-reviewed journals, the show provides insights that impact clinical practice and patient care. From the journal Neurology and the American Academy of Neurology, providing education and expert analysis since 2007.

    Advertise

    Copyright: © 2019

    • Apple Podcasts
    • Google Play
    • Spotify

    Latest Episodes:
    From the Mailbox to the Microphone - Part 2 Nov 19, 2026
    Show notes

    In part two of this series, Dr. Stacey Clardy talks with Drs. Jeff Ratliff, Andy Southerland, and Jason Crowell about memorable podcast interviews, the value of human connection and practical clinical education, and the podcast's evolution over the years. Read the related article in Neurology®. Nominations for the 2027 Ted M. Burns Humanism in Neurology Award will be open until December 18, 2026, at 3:00 pm CT. Disclosures can be found at Neurology.org. _______________________________________________ Dr. Jose Merino: This is Jose Merino, editor-in-chief of the Neurology family of journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening and have a great week. Dr. Stacey Clardy: Hi, this is Stacey Clardy from the Salt Lake City VA and the University of Utah. Today, we're back with part two of our 20th birthday of the Neurology Podcast discussion with Andy Southerland, Jason Crowell, and Jeff Ratliff. We got talking, can you imagine it, the four of us? It turned into a long discussion, and so today is part two. Take a listen to the first episode. It'll make a lot more sense if you do that. I hope you enjoy the discussion. All right, I want a favorite from each of us. So what's an interview you still think about that you conducted, Jason? Dr. Jason Crowell: Yeah, someone ironically, the one that always comes to my mind is back in 2020, I interviewed Sonia Vallabh, which you all may remember. She is a scientist in Boston. She is very smart. She graduated from Harvard Law School and had a career. And then in 2010, her mother developed fatal familial insomnia and passed away. And then it was found that she had this epigenetic etiology and then Sonia was tested, and she had inherited this mutation, and she and her husband took it upon themselves to try to figure this disease out and try to come up with a cure. And so they went back to school and graduated in biomedical science and were working at the Broad Institute when I interviewed her. And she just has an incredible story. She's incredibly eloquent. And to hear her speak to her family's experience of having her mom suffer from this disease and then the knowledge of this mutation and then her decision to do something about it is just incredibly impactful and really inspiring for someone to go through this and make up their mind that they're going to do something about it. Dr. Stacey Clardy: And as you know, we just recently had both of them back on because they're now in clinical trials. They have a trial in NeuroNEXT for prion disease and the ability to follow those stories over years on the podcast is also something remarkable because we've always had the editorial freedom to do that from all of the editors-in-chief of Neurology. If it's relevant, if it matters, it doesn't have to be published in a particular journal. It should be featured. We've always been encouraged. If it matters to neurologists, then we should cover it. And that was a perfect example of that and how we can continue to follow up and stay on top of particular stories of tremendous meaning to our field. What about you, Jeff? Dr. Jeff Ratliff: Even before I share this, we were just talking about what's the value of having the conversation with an author or with an individual, the value of a podcast, and what can come through in those conversations. And so my episode that sticks with me was actually getting to interview Avi Nath after he was awarded the Ted Burns Award for Humanism in Neurology. And it was in 2024 and listeners of the podcast had gotten to hear Avi's voice as we were going through the pandemic and talking about the neurologic implications of COVID-19. And he was so critical in teaching our listeners at that time. But in 2024, that interview was really about him and giving him a chance to reflect on his career as someone you could look at his website, you can look at PubMed, and you can see contributions that he's had to science in neurovirology. But to hear him talk about being at the bedside of patients with HIV in the '80s when there was so much stigma associated with people with HIV at that time and how important it was to him to take care of patients and to not just learn about their disease, but to care for the people with the disease. And I remember that approach and that Avi's had a tremendous impact on neurology as a scholar, but hearing about that sort of humanistic physician-to-patient approach that informed his science and informed his career was really meaningful to hear about. That's a thing that, as you've already said, Stacey, it's hard to put that through in a publication in a paper. We have the privilege to hear those stories when we have conversations with people. Dr. Stacey Clardy: I agree. And I have two, I don't know if I would say favorite, but interviews that I knew were changing me while I was conducting it, so incredibly impactful. The February 7th, 2022 one where I was able to interview Dr. Daniel Drubach about his experience diagnosing his own Lewy body dementia. And Daniel Drubach, of course, is both a cognitive and psychiatry-trained neurologist working, had just recently retired at that time from the Mayo Clinic. And with his expertise, the ability to describe again what our patients were experiencing as he stepped through each part of that journey was incredible. And then also as part of that, thanks to our great editing staff, we were able to incorporate his music because he's an incredibly talented musician. And so that ability, again with audio to even further the story, while I was conducting that interview, I just was overwhelmed. The learning, the emotion, the humanity of it all. And then I would say the other interview, which was challenging was December 27th, 2021 for the journal's 70th anniversary. And we're of course now in the 75th anniversary, but at that time, it was the 70th anniversary of the journal. And so we were interviewing past editors-in-chief and putting together that story. The Neurology team wanted to incorporate the podcast. And so I was able to interview Ted. And so the assignment was talk about the podcast and how it is an integral part of what the journal does. The unspoken part of that interview though, in 2021, both of us knew this was a chance for Ted to give his voice to the podcast story for the last time. You can listen to that interview at about minute 17, part two in December 2021. And we just included a small snippet at that time, but that interview was very long. It was very hard because we knew we were recording the history. And so very hard to do both of those interviews, but wouldn't have changed those opportunities for the world. But what all of us are getting at is both the privilege, but the incredible pressure of being a part of someone telling their story in real time and trying to steward it. And Andy, I guess you kicked us off, but do you have any other favorites? Dr. Andy Southerland: There are a lot of great interviews over the years reference to the opportunity to interview people who are leaders in the field, and that's always exciting. I'd say that one of the coolest things about being part of the podcast though, and we've each talked about it a little bit, was just that the podcast really does cover the broader humanity of neurology. And Ted was really big on that. He would always say, "Tell me one thing you've learned about neurology today, but also tell me one thing you know that is not necessarily about neurology." And so he wanted us to interview human interest stories that were neurology-adjacent. And probably one that sticks out to me, I still think about it all the time actually, is I had a chance to interview the novelist, Puerto Rican novelist Esmeralda Santiago back in 2014 who had herself suffered a stroke that affected her Wernicke's area of the brain, and she had a pure alexia and some receptive aphasia. And she had taught herself to read again, both in English and Spanish, and to write again, and she actually had published a novel after her stroke. And Ted heard about it, and we connected with her. And he allowed me to do the interview, and it was just amazing, and I encouraged folks to go back and listen to that interview. And she still is writing today. And I think about it all the time with my patients who have aphasia and are trying to relearn those same skills. And we talk about it with students and residents about folks that are multilingual and how that affects their language abilities. And that one sticks out in my mind as it were. Dr. Stacey Clardy: That's a great one. And of course, we make all of the episodes sound so seamless, but time to fess up. So Jason, I'm going to start with you. What is the funniest thing that's happened while you were trying to record an episode? Dr. Jason Crowell: So Ted had this idea, it was like 2018 or 2019. I'm not sure what sparked it, but he had this idea that we should go back and find every neurologist or neuroscientist who had been awarded a Nobel Prize and invite them to be on the podcast. I said, "Okay." And so we sent emails and Stanley Prusiner, recipient of the 1997 Nobel Prize at UCSF said he would come on. He, of course, discovered prions and I was nervous for this. This is a big one. This is Stanley Prusiner, Nobel recipient. And so I had my notes ready, and we start recording, and I was trying to just improvise on the spot and make it sound conversational. I was like, "Tell me, how did you decide to go into this field of prions?" And he was just not disrespectful. He was just like, "I didn't. It wasn't around. I came up with it." He wasn't being boastful, but I portrayed him as choosing to go into this field that didn't exist because he discovered the thing. So I wish I'd worded that one differently. Dr. Stacey Clardy: Oh, that's great. And I remember I was able to do one with Peter Doherty, and I remember ahead of it being explicitly told, "This is no different than every other interview that we do. And so you will call these folks by their first name." Talk about wildly uncomfortable. I mean, it's bad enough when you're, say, a trainee or junior faculty like we were, but then to just get onto this podcast, be like, "Hey, Peter." But of course, the lesson there was these are real people and they do just want to have a conversation. But I crack up every time we have a new interviewer and they struggle with the same thing when I'm going back and editing and I have to edit out 14 or 15 times when they're saying Doctor instead of the first name. And I always think of just chatting it up with the old Nobel laureate. It's a great one. How about you, Jeff? Dr. Jeff Ratliff: So this one involves Jason, and I'm glad he didn't take this story away from me. During the height of the pandemic, we were working on a two-part series about movement disorder emergencies, and Jason and I were taking turns interviewing each other and had built a script up. But for context, this is the year 2020. We are all at home. I have a two-and-a-half-year-old running around the house. It's July, and we couldn't quite get the reverb on the audio to go away in the office in my house. And so finally, the solution that I had to resort to was grabbing a blanket and throwing it over my head, over the microphone, over the laptop while I'm talking to Jason. And so we're talking there about movement disorder emergencies, and I am sweating onto everything. It's just I'm uncomfortably warm. And Jason had some great banter. I still remember it, but it was another moment to be thankful that it's an audio-only medium because there was nothing aesthetically pleasing about that video experience if we had to subject ourselves to it. Dr. Stacey Clardy: Oh my goodness. Yes. I remember at some point, adding in an introduction to say, "Hey, listen, the audio's essentially really going to take a dive in these coming months. We don't know for how long." But yeah, we had worked so hard to perfect the audio, pandemic comes along, and you under a blanket and so many of the people we are interviewing in just hilarious positions. Andy, do you have a particularly fun memory of things going perfectly well? Dr. Andy Southerland: It's great to hear Jeff tell the story of a podcast interviewer's life. Surely the show must go on. And the beauty of podcasting is you can do it from anywhere as long as you've got good audio. And so not necessarily a story of something gone wrong, but I know I had to do a podcast interview early on one time, and it happened to coincide with my brother at the time was getting married and we were on a golf trip. And I remember specifically on the golf course having to step over into the snack shack that was the halfway house at a golf course. I won't say which one because that's probably some branding issues we'd have. And I did a podcast from the men's bathroom at the halfway house on the golf course. I won't even say who I was interviewing at the time. But I have to say when I went back and listened to it, other than a mild echo and occasional "Fore!" in the background, the audio [inaudible 00:12:55], and it wasn't a birdie, but it was a solid par that day. Dr. Stacey Clardy: Oh my goodness. And we should probably acknowledge here that there is a keeper of all our secrets who really we view as essential and we know we can't function without, but that's Anna Rehbein. She's even on this discussion. She's running it. She's keeping us in order. Anna, I want to put you on the spot. What have you had to do? Because really when things go terribly wrong and we can't fix it, we text Anna or call her or just throw our hands up. Anna, tell us your experience. Anna Rehbein: I remember sitting in on my first podcast recording when I got the job four years ago, and it just not going well whatsoever. There was a terrible echo. And going along the lines of Jeff's story, I had to ask somebody that was very high up at an organization, very well known in the field to ask them to go sit in their closet to do the recording, and I just felt so bad. I was like, "Oh my gosh, they are not going to want to come back onto the podcast." And at the end, they were so grateful for the opportunity and we've had them back on the podcast since. But I remember thinking, "Oh my gosh, I'm going to lose my job. This is the second week on the job." Dr. Stacey Clardy: Yeah, it needs to be done. Ultimately, that's the same thing as interviewing all these very famous people. They also want to sound good. And along the way with the podcast changing format, changing segments, one of the fun things that everyone on this call was involved in was right around 2018 and into early 2019, we were looking at the world around us and seeing that there were home devices, smart devices, cars where you could open up your door, turn on the ignition and then say, "Give me my news." And out of that spun the discussions of we really need to have a way to utilize that time. So the Neurology Minute daily briefing, right? So we will always have a need and everyone will always love a long-format podcast, but the discussions began to center on other ways to get people the neurology information they need depending on their lifestyle or that era of their career. Jason, tell me what you remember inspired the idea, what your recollection is of how the Neurology Minute daily briefing came to be. Dr. Jason Crowell: Yeah, S…

    Full show notes at the publisher

    From the Mailbox to the Microphone - Part 1 Nov 16, 2026
    Show notes

    In part one of this series, Dr. Stacey Clardy talks with Drs. Jeff Ratliff, Andy Southerland, and Jason Crowell about the evolution of the Neurology® Podcast, from Ted Burns's founding vision to the conversations and formats that have connected with listeners for nearly two decades. Read the related article in Neurology®. Nominations for the 2027 Ted M. Burns Humanism in Neurology Award will be open until December 18, 2026, at 3:00 pm CT. Disclosures can be found at Neurology.org. ________________________________________________ Dr. José Merino: This is José Merino, editor-in-chief of the Neurology family of journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening and have a great week. Dr. Stacey Clardy: Hi, this is Stacey Clardy from the Salt Lake City VA and the University of Utah. We are featuring a two-part series today. I'm joined by Jeff Ratliff, Andy Sutherland, and Jason Crowell. We're celebrating 20 years of the podcast and discussing everything that happens behind the scenes, what goes into it, and what really matters and has allowed for success over 20 years. We ended up talking, we got going, and it turned into a really long interview, so it will be broken into two parts. This is part one, and we'll start now with the beginning of the discussion. The four of us, along with AAN and Neurology staff, recently researched and wrote an article in Neurology. We titled it, From the Mailbox to the Microphone: The Neurology Podcast and the Evolution of Medical Education. It gave us a great chance to revisit 20 years of podcasting as part of the even greater milestone, which is the 75th birthday of the Neurology journal. So Andy, Jason, Jeff, this is a first, but it's great to have you all here together. Dr. Jason Crowell: Thanks, Stacey. Thank you for coordinating. Dr. Andy Southerland: What a group. Thank you, Stacey, for having us. Dr. Jeff Ratliff: Yeah, it's great to be here. Dr. Stacey Clardy: I want to understand your experience with the podcast. We've all had unique experiences and really understand what the last 20 years have been like through your memories. So let's start with you, Andy. I want you to take us back to Ted Burns, the podcast founder at UVA. John Noseworthy invited him to lead the journal's podcast after hearing his work with AANEM, and the first episode then followed in September 2007. And I would be remiss if I didn't take this opportunity to announce that the Ted Burns Humanism and Neurology Award is now accepting applications for 2027. You can find the link to nominate in the show notes. It's also if you go to the americanbrainfoundation.org/tedburns, you will find the announcement and how to nominate someone who manifests humanism in our field. So what do you remember about how Ted got people excited about this and how did you get pulled into this? Dr. Andy Southerland: First of all, Stacey, it's amazing to me that in this upcoming year, it'll be 20 years that we've been doing the Neurology Podcast. As you said, the first episode aired in September of 2007, and this time next year we'll surpass that 20-year mark. And what I remember about it is in 2007, I was a PGY-2 neurology resident here at the University of Virginia, and Ted Burns was my residency program director. And he had been talking about the idea of podcasting, and mainly because his residency, Ted viewed it as a new way to help us be educated, to give us readily available access to listening to world experts in the field of neurology, talk with other experts. It's hard to imagine, but back then I didn't know what a podcast was. Not many of us knew what a podcast was in 2007. And Ted really got his start in two ways. One, you referenced he began doing an audio cast for AANEM. Ted was a neuromuscular neurologist and he developed an educational audio cast for that organization. And the other provenance of the neurology podcast vis-a-vis Ted's vision, interestingly enough, came from his love of wine. Ted and some of his buddies started a wine and porting company. And by virtue of that, in addition to talking about neurology, Ted wanted to talk about his other favorite subject, wine, and started an audio cast called Grape Radio. I kid you not. And not only was that a popular wine audio cast or podcast at the time, but Ted was a finalist for a James Beard Award for media as it related to food and wine. I think the year that Ted was a finalist, while Martha Stewart and her television program actually won the James Beard Award that year for food and wine media. But anyway, so the neurology podcast has deep roots both with Ted and his mentorship over us, but also proverbially in the roots of the vineyards here in Central Virginia in some ways. Dr. Stacey Clardy: That's wild. And actually I'm now looking at the dates and hearing you talking. And I interviewed at UVA for residency and it was actually later in 2007. I guess at that time he was already talking about it and working it into residency interviews. I'll never forget it. And he was so enthusiastic about it. I didn't even own an iPod. And when I think back on that, it stuck with me. That conversation as an applicant interviewing at a program was really how I was introduced to podcasts. Jeff, what's your memory? Dr. Jeff Ratliff: My memory, I was also at the University of Virginia. So in this universe of Ted and the podcast, and I remember there was two things Ted would say over and over again. And he would say, "Listen to the podcast. I'm spoonfeeding you knowledge, and drink Williams Corner Wine." He had some skin in the game on the second one and there might've been a conflict of interest there, but yeah, it was baked into the culture. I was at UVA a little bit after Andy finished his training and Andy was still around, but it was baked in and I would hear Andy, I would hear residents ahead of me doing interviews and then I got envious. I was like, "I want to do that. I want to do that." And would ask Ted, "Hey, if there's a good topic or if there's a good interview, keep me in mind, I'd love to get involved." And that was how I got involved when I was a resident there in Charlottesville. Dr. Stacey Clardy: Great point. That's still how it's done. We love when people volunteer, raise their hand and say they want to be involved. Jason, how did you get roped in? Dr. Jason Crowell: I guess I was first exposed being on consults with Ted and he would pull us into the resident room and we would've had another consult for confusion and someone in the ICU and he'd be like, "Man, we had a really great two-parter on workup of encephalopathy." And he would tell the medical students to pull it up and listen to it. And so again, it was baked into the culture, as Jeff said. I was finishing my residency in 2017 and Ted had been encouraging me to do an interview. And so I was selected to do an interview with Nicholas Johnson now at VCU, to talk about a health policy act that had been put into place in Congress. And I remember being so nervous and I was so anxious. I can still remember sitting in the resident workroom in the basement of the clinic. And one of my other residents was in there and I jumped on the call, and it was done in four and a half minutes. There was no banter. You would think that I had just done a live shot on cable news. And I got off and she was just like, "Was that it?" "I think so. I think that was it." So that was one of the first lessons that I really took away was you know it in your head that it's not live, but man, it feels live. Our audience doesn't even know right now, but I'm doing my third take of this very answer to your question and nobody knows because it's not live. You can just do the edit over and over again. That was key for me to improve my skill as an interviewer, was remembering that the editing can take care of a lot of it. Dr. Stacey Clardy: Although back then the editing was not what it is now and it was on phone lines. So yeah, there was a bit more pressure. And Jeff, your first interview I'm sure was amazing. Dr. Jeff Ratliff: My first interview, I still remember it. And it's actually cool to look back. My first interview was, it was April of 2014 and it was with an author named Vincenzo Donadio, and we were talking about doing skin biopsies of nerves to look at alpha-synuclein in the skin, which is crazy because if we think about topics we've featured just in the past few years about skin biopsy, biomarkers and Parkinson's. And so that was actually my first interview and it was on a landline, probably in the same office that Jason was in, and the connection was not good. He was in Italy and I was straining with every muscle in my ear to hear every bit I could hear of his answers. And I remember Ted looking at my script beforehand and saying, "You're trying too hard. You're trying too hard. Keep it simple." And that lesson too of just ask the questions that the listener wants to hear the answer to. And that lens and that framework was the approach that we still think about now. But yeah, I was convinced Ted was never going to let me near his podcast again after that first interview. So I'm lucky to be here talking with you guys now. Dr. Stacey Clardy: Yeah, I remember always the gentle feedback. He was pretty good with the sandwich. Andy, I didn't listen to your first interview. I assume there was some dad joke in there. Dr. Andy Southerland: I probably developed my comfort with sharing the puns that were going on in my head with the wider audience over the years, Stacey. But I actually had to go back and look and see actually what was my first interview with the podcast. And it's actually really interesting because it speaks not only to the educational quotient that we've all talked about in our time mentoring under Ted, but my first interview was in August of 2009. And I was asked to interview or given the opportunity by Ted to interview Pooja Khatri, who many people out there listening will recognize as the current chair of neurology at Yale University, who was a longtime vascular neurologist strokeologist at University of Cincinnati and PI of practice changing clinical trials. But at that time, there was an article that she and her team at Cincinnati published in the Neurology journal, and I'll tell you the title because it's meaningful, Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. And that is a concept that we know to be self-evident today. And it was based on data from the original interventional management of stroke in the vascular trials, predating, of course, all the eventual trials that showed that endovascular therapy for stroke was a life-altering, outcome altering therapy. At that time, we still didn't know that. And here I was as a neurology resident getting to interview an up-and-coming clinical trialists in the field about something that eventually would be groundbreaking. And that was all because of Ted and the podcast in that original 2009 interview. And so that's really cool. I wonder if Dr. Khatri remembers that interview as well. We were probably both nervous at that time. Dr. Stacey Clardy: Now you're old pros. I suppose you touch on a little bit of the brilliance there too, interviewing the authors themselves many times who were just as shy and nervous as we were. And we take this for granted now, but there's a reason why this is brilliant because if the questions are framed correctly, the art of it, the conversation gives you so much that isn't in the paper, and it brings the author's expertise right into your living room. I don't know about you guys, but this is where mid-interview now that we all have so many interviews under our belt, this is where in the middle of the conversation, I'll just take it off the rails now because without fail, the people we're interviewing always say something fascinating. It usually, in my mind, goes right back to a patient I've seen or a question I have. And you've got the expert on there and you can ask them. You can say, "Yeah, I know this isn't in your paper," but that is really the brilliance that all of us were taught and learned. I don't know what your thoughts are here, Jeff, if you remember the first time this was happening or even recently when this happened to you. Dr. Jeff Ratliff: So one of the other lessons that I keep in mind when we're talking with the authors is it's so important to them that they bring all the context, they've done the background research, they've done the work leading up to the publication. But it's critical to them that the listener and we in neurology can understand what's going on with the project and why it's important. And I remember it was 2019 and I was doing an interview with Michael Fox. We were talking about his work doing brain lesion mapping to try and understand dystonia. And I'll admit, I was maybe even struggling a bit in the moment on how to take these concepts of brain connectivity and brain lesion mapping, and to bring it into the clinical sphere and to make sure our listeners understood what we were trying to do. And I ask a question and he gives an answer. And then he says, "You know what would be a great question to ask?" And right off the cuff, and I wish I could remember it, he formulates this question and he said "Then we could talk about this." And his advocacy to make sure that we took this opportunity to bring the topic to the listener and make sure that we could understand it this way. So if you ask me this and then we could do it this way and the collaborative nature of working with the authors is really valuable. Because we say this amongst ourselves all the time that we want them to sound good, but we want them to have that opportunity to teach the audience about their work and why it's important. It stuck with me that he and I had the same goal in that interview. Dr. Stacey Clardy: I remember that interview really well. I'm not sure that the paper would've gotten me there and there's no place as an author of a paper to put in why it matters, why you should read it, why you should care. That's just not how we structure scientific writing. And we've played with a lot of ways to do this, ways to bring the messages to different components of the audience because we're so fortunate. It's a huge international audience and it's everyone from patients to trainees to world experts in neurology. And so we've had so many format changes over the years. You guys were sharing your first interviews. I was fortunate when I came in, I was able to get started doing resident and fellow clinical pearls, which were much easier than being thrown into the deep end and interviewing a world expert. And so many people remember those when we had the resident and fellow clinical pearls. That was when the podcast had broken up different segments. Often there was a lesson of the week in there as well. Somewhere back in there is when we brought in Delayed Recall, which we still have kept and feature separately. Andy, which part of that history and the different segments do you remember? And I guess is there a format you'd be tempted to bring back or introduce? Dr. Andy Southerland: Yeah. And one thing again with Ted that he instilled in those of us who continued on the podcast, and Stacey, you've continued to do it well with Jeff and folks today, is to constantly b…

    Full show notes at the publisher

    Establishing Potosi Virus as a Human Pathogen - Part 2 Nov 12, 2026
    Show notes

    In the second episode of this two-part series, Dr. Stacey Clardy talks with Dr. Justin Abbatemarco about the risks of immunosuppression for autoimmune neurologic diseases and how to optimize the benefits of immunotherapies while minimizing the associated risks.

    Read the related article in Neurology®.

    Disclosures can be found at Neurology.org.

    ________________________________________________

    Dr. Jose Merino: This is Jose Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening, and have a great week.

    Dr. Stacey Clardy: This is Stacey Clardy from the Salt Lake City VA, back with part two of our Bugs and Drugs in the B-cell Era Depletion podcast with Justin Abbatemarco. We're talking about things that have come to the forefront in terms of infections and how they present and how to prevent them in B-cell depleted patients, but also as it applies to folks with immunocompromise of all varieties. We discussed specifically the Potosi virus in part one, and here we're going to talk more broadly about common viruses that our patients encounter and how we address this, what we can do to prevent things, and cautions around making sure patients are vaccinated, but being careful with those live vaccines as well. I hope you enjoy. Justin, how do you approach, first of all, anti-CD20 dosing, or what can you do to mitigate the effects of any therapy? And how do you feel about the possible role of immune globulin treatment here?

    Dr. Justin Abbatemarco: It's such a challenging scenario, and sometimes asking for some help with our colleagues, allergy and immunology is a big part of our practice here. And asking whether or not possibly supplementing with IVIG, if especially their IG levels are low, is something to at least think about. As you've talked about in the podcast many times, we should get all of the samples that we need, both in serum and CSF before initiating IVIG because it can cloud all of those results. And so saving those samples beforehand. And also again, acknowledging that there's not great data to help support this. Maybe the best data is within the West Nile literature that it's possible IVIG, especially if it's pooled around that area, might have relevant autoantibodies to help that patient fight off infection, and was published in some of the reports you've already mentioned. And to see if that would offer any chance, again, in these really challenging spots where we don't have effective vaccinations, we don't have effective antivirals, and how are we going to help patients? It's a multidisciplinary discussion. How do you think about it in your practice?

    Dr. Stacey Clardy: The same, really. We're in autoimmuneology, so we're accustomed to having discussions where there isn't high-quality data. We all are equally frustrated by the fact that usually at best we can discuss low-quality case series, retrospective studies. And so I explain that whole concept of what I'm coming to the table with, to the family and to the patient, and say, "This is low-quality data. I want you to know that," so that they understand the level I'm presenting and the level they're making a decision with. Of course, yes, always preserving those samples and the ability to hopefully find out in the future more of what's going on. But when you're in the hospital, when you're ill, when you're decompensating, those specific patients, yeah, certainly we have for West Nile cases given intravenous immunoglobulin as part of supportive care, but full well acknowledging to everyone, the family, the patient if they're well enough, the teams, this is a bit of a Hail Mary, and it's theoretical, just hoping that particular donor pool might be able to offer some prior infectious exposure immunity to the patient that's receiving that. So yeah, pretty much the same as you, I would say. And you're making me think back to what you said about vaccines. That's a fraught discussion and one where I have had to do a lot of education to two big points that I always have to refresh on. One, we can't do live vaccines after they're on that B-cell therapy. And the other one is counseling patients on what vaccinations actually do. And this one's coming up now because here we are November. So I've been having the influenza vaccine talk at every single visit. And many patients say, "Okay, I'll get the flu shot because I don't want to get the flu." And I immediately pause the conversation, and I say, "Look, that's not what this vaccine does. You are still going to get the flu if you're exposed to the flu virus in the sufficient environment, in the sufficient amount." I say, "Our goal here," particularly for those on immunosuppression, "our goal here is that if you are vaccinated, we hopefully keep you out of the hospital. We're hopefully lessening the severity of the infection that you are going to get if you're exposed in the appropriate setting." And it's amazing to me that the large majority of folks forget that. I don't know if that's your experience.

    Dr. Justin Abbatemarco: The same exact experience. I wish I could just have my answer on a loop just so I could help, but it's an important conversation we have to have. The other thing that came to mind was patients saying that before they were on treatment, "I never got the flu and so I don't need the vaccine," and trying to shift their mindset to be like, "Absolutely, hear that, but your risk profile has profoundly shifted now." We've got to change that thought process a little bit. And yes, that when you get the vaccine, you might not feel well for a few days, but much better than going to the hospital or even worse outcomes that we know can be associated with flu and other bugs.

    Dr. Stacey Clardy: And particularly around the holidays, it becomes a perfect storm. And so I do try to acknowledge this in some of our conditions more than others that I jokingly say, "Hey, you have a doctor's note from me not to spend any time with anyone who stresses you out around the holidays." Because it's also that everything that happens when people holiday, so sleep disruption, poor diet, and probably most importantly, the emotional stressors that have impacts on the immune system that we don't even begin to understand, except that we see it. We see that patients do worse with autoimmune conditions when they take those emotional hits. I believe my patients, they go to a stressful funeral, and that's their first symptom. So I try to give them this whole package of a talk and say, look, if they stress you out anyway, if they tell you they have a sniffle, that's a no-go because you put the perfect storm together, you're going to get sick, even if you do some Purell and things like that. So take yourself out of those situations. And usually, it's at least good for a bit of a chuckle from the patients, but also I hope that they're internalizing that into the entire, to your point, lifestyle. This is a different you. This isn't the you that never got the flu before you were immunocompromised. This is a new you and one where you have to pay attention not just to the germs, but the entire setting around that. I don't know if you do anything like that, but it at least helps sometimes, hopefully, to lighten the mood.

    Dr. Justin Abbatemarco: I was going to say, it feels like it's going to become like an in-laws talk. I don't know how those conversations to help or is the smart phrase in the letter being like avoid your in-laws.

    Dr. Stacey Clardy: Rough. Poor in-laws. Everybody's an in-law. Yeah, no, same. Going back to your original case and the things that are going to perturb all of us deeply about that, being that the onset was not dramatic, this was not a patient that landed in the ICU after going out hiking, what are you doing now? What do you advise we do when someone on an anti-CD20 therapy or other significant immunosuppression develops otherwise unexplained cognitive or behavioral decline? What's the one thing you really want us to learn and do differently after that particular presentation of a virus?

    Dr. Justin Abbatemarco: Some themes that we've hit on and things I've incorporated in my practice is that moving away from these traditional risk factors that I would've previously associated with CD20s, so age, time on therapy, their disability, their IgG levels. Yes, those are some markers that we could use, but I will not be married to those to think about their risk of infections on these classes of medications. I think two, the CD20s can really mask the degree of inflammation that we can see or the serologies. And so being a little mindful of how we incorporate testing and maybe a little sooner metagenomic next gen sequencing if we can get that in the spinal fluid. And again, just having this higher on that differential and being a little bit more mindful about prevention, and all the different ways we talked about. Those are some things that we're really going to think about, and hopefully help our patients and family members moving forward.

    Dr. Stacey Clardy: Yeah, these are great points. And now you've just made me think of something else. All these ghosts of patients past good syndrome. I know you're familiar with that, but again, it's not just the CD20 patients, it's these patients walking around who don't know that their immune system is not normal. And I've been involved in the care of several folks now with good syndrome. And so what is that? They don't teach us what that is in neurology, but it's an immune deficiency. And these folks can also be hovering around our clinics with things like myasthenia gravis and other unusual autoimmune conditions. And those are the patients that really drove home for me asking the infectious exposure questions, the infectious history, sinus infections, bronchitis, urine infections, skin infections, the hangnail that didn't heal, or, oh, just a little bit of MRSA, but it healed up, those things all together because those patients essentially have really an undiagnosed immune deficiency that causes frequent infections that some may not recognize are too frequent, superimposed with autoimmunity. And if we don't pick up on them because they come in and we're going to treat the autoimmunity, goodness, we've really doomed them to some awful things too. And so there are other reports out there, other than the Potosi virus, and some of those reports are in these patients of just really being unable to clear viruses chronically from their brain. So it really is a great example of caution for me on these medications, but also just listening to those patients and caution in any patient that comes in where it doesn't quite sound right. As you said, she was young. There was nothing right out of the gate except why the cognitive changes, why this stuff. And I think they're out there more than we realize. CD20 agents are going to bring them to the forefront, but this still occurs naturally as well.

    Dr. Justin Abbatemarco: I'm guessing you picked up some of those cases, like good syndrome, by doing testing before you started immunosuppression?

    Dr. Stacey Clardy: I have. So things to think about, especially, we didn't even talk about this, but measles titers and measles vaccination, what do we do with that in rituximab? That's a live vaccine. So we can check our patient's IgG, which is again only half the story. For example, you may get a low IgG, and they may actually have some immunity on that titer because, depending on the rituximab or the other B-cell agents, how long they've been on it, but it's a good reminder. That's a discussion that I've been incorporating as well, especially in the last one to two years. What's your measles status? Were you vaccinated? How many times were you vaccinated? How old are you? Meaning, how did that inform the vaccine strategy when you were younger if you did? And if you didn't, again, that extra layer of, oh, this is serious. Are you a teacher? Are you a healthcare worker? What area of the world do you live in, and how much are we seeing resurgence of measles? I don't know if that's come up in your clinic, too.

    Dr. Justin Abbatemarco: It has, and I agree. It's just such a difficult conversation. People aren't usually aware. I appreciate your comment. The measles lab test is imperfect, so that's not a great marker. And then a live vaccination, have to be thinking about this before you open this door, maybe a Pandora's box with these immunosuppressive medications, but it's such a difficult topic to explore with patients and their families.

    Dr. Stacey Clardy: The one we have to explore. That much is clear. That's our job. If we're ever writing a script for an immunotherapy, we've got to discuss all of these things and be thoughtful and give patients references for them. In the era of the electronic medical record, this is very easy to incorporate all of these things. Justin, it has been a great review for me and learning. Thank you for walking us through all these scenarios, things to think about. This helps me to continue to shape my approach in clinic, and this two-part podcast has been thought-provoking. So thank you for that, and thank you for publishing your paper. The title again is Establishing Potosi Virus as a Human Pathogen: Fatal Neuroinvasive Disease in a B-Cell Depleted Patient. It is in Neurology. Thanks, Justin. This is Stacey Clardy, your podcast editor. If you've enjoyed the podcast, please take a few moments to subscribe, rate, and review the Neurology Podcast through Apple Podcasts, Google Podcasts, Spotify, or wherever you listen. And remember, you can always head to neurology.org/podcast for our full list of past episodes, or you can also search by keyword in your podcast app for any neurology-specific topics you want to learn about.


    Establishing Potosi Virus as a Human Pathogen - Part 1 Nov 09, 2026
    Show notes

    In part one of this two-part series, Dr. Stacey Clardy talks with Dr. Justin Abbatemarco about why infection can be overlooked in people on anti-CD20 therapy and practical ways clinicians can improve testing, prevention, vaccination, and collaboration with laboratories and infectious disease specialists. Read the related article in Neurology®. Disclosures can be found at Neurology.org. _______________________________________________ Dr. José Merino: This is José Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening and have a great week. Dr. Stacey Clardy: This is Stacey Clardy from the Salt Lake City VA and the University of Utah with a two-part neurology podcast. Today, we're talking about infections, specifically in people receiving anti-CD20 therapies, but also good food for thought and folks who are otherwise walking around immunosuppressed. And there's a case that inspired this podcast. So joining me to talk about that is Justin Abbatemarco from the Cleveland Clinic. You know him well as one of the voices of the podcast. He's also an autoimmune neurologist and he's the author on this report. The title of the report is Establishing Potosi Virus as a Human Pathogen: Fatal Neuroinvasive Disease in a B-Cell-Depleted Patient. Justin, thanks for agreeing to be interviewed today instead of leading the interview. Dr. Justin Abbatemarco: It's much less comfortable on this side of the mic, Stacey. Dr. Stacey Clardy: Yes. Yes, it is. But hey, we're all friends, so we'll just chat. So Justin, your report establishes that Potosi virus, which I have never heard of, can cause fatal encephalitis in humans. So what is this virus and what do I need to know about it? And what is this case teaching us, especially with our increased usage of all these B-cell depleting agents? Dr. Justin Abbatemarco: This was a really humbling case that we had in service, and I think we have much more to learn about Potosi virus and its interaction with humans and immunocompromised hosts. This is only the second report and the only one with pathology to help confirm it. But the virus has been known for a really long time. It's been documented mosquito populations before this, but it's only been over these last few years that it's been linked with metagenomic next gen sequencing as a potential human pathogen. And so more to come. We really hope this report will spur further investigations on this, have this included as a human pathogen on metagenomic next gen sequencing reports. But I think the bigger thought process around here, it made us really think about it at our clinic on how we approach patients on CD20 medications or their immunosuppressive medications. Because the way this case presented initially, it really threw us. Infection was not on the top of our differential. And so some of the learning points about the traditional risk factors and how we think about testing, those are some major takeaways we had when we look back at this. Dr. Stacey Clardy: So tell me about this. What did you think was going on? I read that her MS seemed to be fairly well controlled on a B-cell depleting agent. So how did she present so that it can scare me even more that I'm missing this? Dr. Justin Abbatemarco: I know, it's so humbling. But she was 37, she was diagnosed with MS over a decade ago. She had been on some of our platform medications and in 2020 started rituximab and did incredibly well. Minimal disability on examination. IgG levels were normal. She actually worked in our hospital and by about four years on therapy, she starts developing some subtle symptoms, feels like she's having a hard time with attention processing, things we hear about all the time in clinic. Dr. Stacey Clardy: Yeah. Dr. Justin Abbatemarco: Everything looks stable from an MRI perspective, so we continued along. But a few months into that course, she's unable to maintain employment. She had severe neuropsychiatric deficits. So we brought her into the hospital, extensive evaluation. The only thing that popped forward was that she had six cells on her spinal tap. All the conventional studies for autoimmune diseases, other infections, even prion diseases were evaluated and nothing came up. Over those coming months, I think what stood out was that her MRI showed this dramatic global atrophy and the paper, the figure will do better than anything I could describe in words, but some of the measures including her whole brain atrophy measures were just off the charts, which is just not typical of MS at this point. And eventually we were able to get metagenomic next gen sequencing, which identified this virus. And then through the work of many people to get this report across, including our colleagues across the CDC and many across the Cleveland Clinic research campus, were able to prove that the virus was within the neuron and likely drove the cause of death here. Dr. Stacey Clardy: So some of this was postmortem on that brain tissue, is that right? Dr. Justin Abbatemarco: Definitely, just because there hadn't been proven on pathology before. So I think that was a really important part of this case. The previous case report had just mentioned this on metagenomic next gen sequencing, but left open the ultimate cause of death. Dr. Stacey Clardy: And you can of course see the images and you should go do that. This is published in the Green Journal. You raised the point that it wasn't so much the dramatic white matter changes, it was atrophy. Is that right? Dr. Justin Abbatemarco: Yes. Without other evidence of inflammation within the CNS space, six cells was just one over the reference range, just not the dramatic presentation we expect with a CNS infection. Dr. Stacey Clardy: And you said her IgG was normal at her last rituximab infusion, is that right? Because that's usually a marker we look at to say, "Oh, maybe this is someone who's susceptible." But her IgG was normal? Dr. Justin Abbatemarco: Yeah, before the onset of these symptoms was normal. The other risk factors I think about too, age, she was 37, minimal disability on examination. Her EDSS was one to two. And so those traditional risk factors that are in my mind and when I'm counseling patients, she had none of those. Dr. Stacey Clardy: But then down the road you said her IgG did drop, but that was after this virus took hold, right? So in other words, it didn't protect her having a normal IgG. Is that fair? Dr. Justin Abbatemarco: She was also on lots of other medications that could have confounded the IgG level. I know you've talked about that a lot on the neurology minute, and so it was a little harder to interpret through the course of her hospitalizations. Dr. Stacey Clardy: So not specific to her, but yes, to your point, there are multiple medications we give in the course of someone's illness, right? Sometimes we give anti-seizure medications or really potent antipsychotics or even high dose methylprednisolone and all of those things can lower IgG and then it becomes a chicken-egg phenomenon, right? So not necessarily specific to this patient, but I understand what you're saying. So with that in mind, you eventually identified this Potosi virus through the metagenomic sequencing of the CSF. Now that you have a result like this, now that you've lived through this tragic case, has this unusual and presumably quite rare result changed how you would send that test in another patient, your threshold, how soon, or are you saying this was a super rare event, maybe not? What has changed in how you practice? Dr. Justin Abbatemarco: Utilizing that test, especially within our autoimmune neuroimmunology population who are commonly immunocompromised, we're going to have a lower threshold to send that off. And we've discussed this in the podcast so many times about the pros and cons of that test, that it's definitely not a silver bullet, but it's particularly helpful in patients who are immunocompromised. And so despite that she didn't have a huge CSF pleocytosis initially and that we weren't sure exactly which bug we were looking for, early evaluation with metagenomic next gen sequencing is something we're going to think about. Dr. Stacey Clardy: And in select cases, certainly this sort of presentation doesn't come along all the time, but I'm old enough now and many folks, if you've been practicing neurology, if you did your internal medicine here, if you're at all in the hospital, we all have what I call the ghosts of patients past. I've certainly seen some patients where we never found a pathogen via all the traditional measures and yet you knew in your core that was the top thing going on. So not a ton of patients, but certainly we all can think of ones where we never quite got to the diagnosis. And we've talked to Avi Nath before too at NINDS, and he also tells us that you can remain negative, even sometimes on the next generation sequencing and ultimately tissue pathology is the only way you can make the diagnosis. Let's talk about some of the more common things that we should be looking for in patients who are on B-cell depleting therapies or otherwise have an inborn error of immunity or acquired immunodeficiency. I'm thinking of another paper by banks and colleagues about enterovirus. The title of that paper is Enterovirus Encephalitis in People With Multiple Sclerosis on Ocrelizumab: Insights From a Multicenter Case Series. And I imagine you're familiar with that as well, certainly with the research for this case report. So in that five patient series, how do you compare, contrast that to this one? What stood out to you there about exposures and how the patients presented with enterovirus? Dr. Justin Abbatemarco: Doing some research for this case report, diving into this literature, enterovirus, really common. One of the more common causes, encephalitis, common with our pediatric population for acute facet myelitis. So it's been out there. And then this case report did highlight that the potential of a severe course with patients with CD20 exposure. And again, some of those same themes in terms of only a few years on this treatment, two, three, five years, that constitutes a huge portion of our clinic. And so these weren't patients that were on it for a decade plus. They were younger, again, with less disability than I would've considered. And then also had this protracted course that was not immediately bringing to mind an infection, and it took a little time for them to get to the ultimate diagnosis. And then these patients didn't have great outcomes either. And so this constellation, I really had to shift my mindset of just being like the traditional risk factors I had thought about with CD20s and infection risk, that they're imperfect to really be mindful of that as patients come to clinic with new symptoms, new MRI changes, and to keep that differential broad. Dr. Stacey Clardy: Yeah. And that paper, if I didn't mention it, is published in N2. In there, I was struck by the fact that four of those patients had recently ill young children, including two cases of hand, foot, mouth. And I balance this in my head now with these therapies are so incredible, especially the volume we see them in with multiple sclerosis patients, but also with the other rare diseases, NMO, autoimmune encephalitis. And so often I'm saying to patients with these therapies, you don't have to worry about the things we worried about 10, 20 years ago. You're going to be able to live your life normally. And then I look at these cautionary tales and go, "Oh, but these are healthy people who are having children, so they are going to be exposed to this sort of stuff." And so I've started to maybe temper even more among the discussions and especially around holiday seasons, for example. And I say, really just tell anyone who wants to visit if they have a sniffle, if they had a GI bug and they say, "Oh, but I've been better for two days." Any of those sorts of things saying, "Hey, just come over in a week. Oh, let's just do that in a few more days." Because the non-immunocompromised population really doesn't think in terms of could they still be spreading an illness? And these are people with full active lives and all the exposures, right? I'm sure you have just the patients I do, and you mentioned in your case, many patients on these therapies are healthcare workers, they are teachers, they are parents. And so what more can we do, I wonder, to caution them? I already give them all my talk about carrying Purell at all times, about wiping down surfaces, especially airplanes or public places with some Lysol wipes, things like that. What else do you do? Dr. Justin Abbatemarco: I think that idea of how to balance this conversation, this is a challenge I face every day in clinic because I'm trying to walk people off the edge. They get these life-changing neurological diagnoses and they want to go into a bubble and the CD20 class, other classes of medications have allowed patients to live full and fulfilling lives with these diseases. And then balancing now with this literature that they can have these really serious adverse events related to these infections. I'm struggling with that same messaging, but I do think I've been more cautious and going beyond just what's been reported in the literature on UTIs and upper respiratory infections that the spectrum of illness that we can see with these medications is maybe clearer than we had initially thought. And so that's been something I've been trying to do to thread that needle with patients and family members about this, but I love your couching around how to talk to friends and family in a practical way. One strategy that we've worked hard, and again, been more mindful over the last few years has been vaccinations. I think rheumatology has been ahead of us in terms of their guidelines and how they implement this, but this has become more of a routine part of our practice. We've had pharmacy integration to really help guide this, but outside of just our age appropriate seasonal vaccinations to talk about other vaccination strategies, including pneumonia and shingles. For these cases, RSV has come out now for our older population, and so really making sure that's a part of the conversation at every visit. How do you handle those conversations in your clinic? Dr. Stacey Clardy: Same. And what I've found out practically speaking, at least in the United States, is when you send these patients to pharmacy or to even primary care settings, you really have to take care to thoroughly document in no uncertain terms in the note, this patient does not qualify by age, they qualify by immune status, and it really is another extra ordeal often with insurance companies covering those vaccines for these patients. As our practice has changed, as we've gotten access to these tools, I really think we have an imperative here. You can't be prescribing these B-cell therapies unless you're willing to take on that work, which is to take ownership of the vaccination, take ownership of the baseline immune testing. Your case points out to us that it's not perfect. We're still going to miss some susceptibilities, but before we're touching these patients, assessing that immune system as in depth as we possibly can, it goes a little beyond the scope of our conversation, but I've found inborn errors of immunity in patients who have a new NMO diagnosis, a new MOG diagnosi…

    Full show notes at the publisher

    Physicians as Patients: A Live On-stage Discussion Nov 05, 2026
    Show notes

    In this special conversation, recorded live at this year's AAN Annual Meeting, Dr. Alison Christy talks with Drs. Franziska Herpich and Yolanda Holler-Managan about how personal experiences with stroke, disability, and caregiving have changed the way they understand and care for patients and families.

    Listen to the previous episode featuring Dr. Franziska Herpich.

    Disclosures can be found at Neurology.org.


    Youth Football and the Epidemic of Pediatric Brain Injury Nov 03, 2026
    Show notes

    Dr. Dara Albert talks with Isaac Thorman about football-related traumatic brain injury in children and young adults and its association with later neurologic and psychiatric outcomes.

    Read the related article in Neurology® Clinical Practice.

    Disclosures can be found at Neurology.org.


    November 2026 Recall: Updates in Neurodegenerative Disease: Diagnosis, Treatment, and Prevention Nov 01, 2026
    Show notes

    The November 2026 Recall features four previously published episodes on updates in neurodegenerative disease diagnosis, treatment, and prevention. The episode begins with a two-part discussion with Drs. Trey Bateman and Gregg Day discussing highlights from the 2026 Alzheimer's Association International Conference. The episode continues with Drs. Sonia Vallabh and Eric Minikel discussing the future of prion disease treatment. The episode concludes with Dr. Pascal Geldsetzer discussing how the herpes zoster vaccination may have neuroprotective effects, potentially delaying or preventing dementia.

    Podcast links:

    2026 Alzheimer's Association International Conference Reports - Part 1

    2026 Alzheimer's Association International Conference Reports - Part 2

    Prion Disease Clinical Trial NN112

    Herpes Zoster Vaccination and Incident Dementia in Canada

    Article links:

    PrP-targeting siRNA Safety & Mechanism Study

    Herpes Zoster Vaccination and Incident Dementia in Canada

    Disclosures can be found at Neurology.org.


    Trends in Emergent Interfacility Ischemic Stroke Transfers Oct 29, 2026
    Show notes

    Dr. Andy Southerland talks with Dr. Matthew Gusler about trends in emergent interfacility transfers for ischemic stroke and factors associated with transfer for care.

    Read the related article in Neurology®.

    Disclosures can be found at Neurology.org.


    Clinical Reasoning: Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia in a Patient With MS Oct 26, 2026
    Show notes

    Dr. Zohaib Siddiqi talks with Dr. Michel Toledano about the diagnosis and management of infectious rhombencephalitis in patients receiving immunomodulatory therapy.

    Read the related Resident & Fellow Section article in Neurology®.

    Disclosures can be found at Neurology.org.


    Incidence and Prevalence of Conversions to MCI and Dementia in Patients With Essential Tremor Oct 22, 2026
    Show notes

    Dr. Matthew Barrett talks with Dr. Elan Louis about the incidence and prevalence of mild cognitive impairment and dementia in essential tremor and what these findings may mean for patient care and future research.

    Read the related article in Neurology®.

    Disclosures can be found at Neurology.org.


    1 2 3 141 Next

    Related Podcasts

    Fresh Air

    1

    Fresh Air Arts
    Twenty Thousand Hertz

    2

    Twenty Thousand Hertz Arts
    The Black Tapes

    3

    The Black Tapes Arts
    Snap Judgment

    4

    Snap Judgment Arts
    Here’s The Thing with Alec Baldwin

    5

    Here’s The Thing with Alec Baldwin Arts
    The NoSleep Podcast – Creative Reason Media Inc.

    6

    The NoSleep Podcast – Creative Reason Media Inc. Arts
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights